CTOs on the Move

Celsis International Plc

www.celsis.com

 
Celsis International plc is a world leading provider of innovative life science products and laboratory services to the pharmaceutical, biopharmaceutical, and consumer products industries through its three business areas, rapid detection, analytical and
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.celsis.com
  • 600 W Chicago Ave
    Chicago, IL USA 60654
  • Phone: 312.476.1200

Executives

Name Title Contact Details

Similar Companies

WHPM Biotech

WHPM Biotech is a Irwindale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Encorium Group

Encorium Group, Inc is a Berwyn, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Softcare

Softcare is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Infinity BiologiX

RUCDR Infinite Biologics Becomes Infinity BiologiX IBX will continue to advance RUCDR`s founding mission to understand the genetic causes of common, complex diseases and to discover diagnoses, treatments and cures for them. IBX will continue to collaborate with – and provide services to – researchers in both the public and private sectors globally, including innovative and market-disrupting sample collection and processing, storage and analytical services, and scientific and technical support in both the research and clinical arenas.

Entrada Therapeutics

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company`s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system.